NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Allergan (botulinum toxin type A) Patient/carer groups	 Board of Community Health Councils in Wales British National Formulary
Action on Pain	Care Quality Commission
Afiya Trust	Commissioning Support Appraisals
Black Health Agency	Service
Brain and Spine Foundation	Department of Health, Social Services
Chinese National Healthy Living	and Public Safety for Northern Ireland
Centre	Healthcare Improvement Scotland
Counsel and Care	Medicines and Healthcare products
Equalities National Council	Regulatory Agency
Migraine Action	 National Association of Primary Care
Migraine Trust	 National Pharmacy Association
Muslim Council of Britain	Neurological Alliance of Scotland
Muslim Health Network	NHS Alliance
Neurological Alliance	NHS Commercial Medicines Unit
 Neurosupport 	NHS Confederation
 OUCH UK (Organisation for the 	Public Health Wales NHS Trust
Understanding of Cluster Headache)	Scottish Medicines Consortium
Pain Concern	Wales Neurological Alliance
Pain Relief Foundation	
South Asian Health Foundation	Comparator manufacturers
Specialised Healthcare Alliance	None
Professional groups	Relevant research groups
Association of British Neurologists	British Neurological Research Trust
British Association for Services to	Cochrane Pain, Palliative Care and
the Elderly	Supportive Care Group
British Association for the Study of	MRC Clinical Trials Unit
Headache (BASH)	National Hospital for Neurology and
British Geriatrics Society	Neurosurgery
British Neuropathological Society	National Institute for Health Research
British Pain Society	Research Institute for the Care of
Institute of Neurology	Older People

National Institute for Health and Clinical Excellence

Matrix for the appraisal of botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Issue date: August 2011

Consultees	Commentators (no right to submit or appeal)
 Migraine In Primary Care Advisors Physiotherapy Pain Association Primary Care Neurology Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine United Kingdom Clinical Pharmacy Association 	 Evidence Review Group Warwick Evidence National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre
Others Department of Health NHS Heywood, Middleton and Rochdale NHS South East Essex Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Matrix for the appraisal of botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Issue date: August 2011

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.